Hamilton Lane Advisors Lowers stake in Nevro Corp (NVRO)

Nevro Corp (NVRO) : Hamilton Lane Advisors reduced its stake in Nevro Corp by 25.17% during the most recent quarter end. The investment management company now holds a total of 59,460 shares of Nevro Corp which is valued at $4,062,307 after selling 20,000 shares in Nevro Corp , the firm said in a disclosure report filed with the SEC on Apr 13, 2016.Nevro Corp makes up approximately 1.91% of Hamilton Lane Advisors’s portfolio.

Nevro Corp opened for trading at $68.15 and hit $69.285 on the upside on Monday, eventually ending the session at $68.89, with a gain of 0.83% or 0.57 points. The heightened volatility saw the trading volume jump to 4,55,311 shares. Company has a market cap of $1,941 M.

Other Hedge Funds, Including , Creative Planning added NVRO to its portfolio by purchasing 121 company shares during the most recent quarter which is valued at $7,232.

On the company’s financial health, Nevro Corp reported $-0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Feb 29, 2016. Analyst had a consensus of $-0.56. The company had revenue of $33.12 million for the quarter, compared to analysts expectations of $32.91 million. The company’s revenue was up 240.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.59 EPS.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.

Leave a Reply

Nevro Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nevro Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.